Albany, NY -- (SBWIRE) -- 08/22/2019 -- Bacterial Vaginosis Market Insights, Epidemiology and Market Forecast-2028
1. Bacterial vaginosis is a common gynecologic infection, affecting nearly 29% of women in the US.
2. Bacterial vaginosis is a common infection estimated to affect approximately 30% of women worldwide.
3. Bacterial vaginosis is present in at least 15% of the sexually active population and this makes the disease 3–4 times more common than urinary tract infections.
DelveInsight launched a new report on Bacterial Vaginosis Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Bacterial Vaginosis market report covers a descriptive overview and comprehensive insight of the Bacterial Vaginosis epidemiology and Bacterial Vaginosis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Bacterial Vaginosis market report provides insights on the current and emerging therapies.
3. Bacterial Vaginosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Bacterial Vaginosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Bacterial Vaginosis market.
Request for sample pages
"Bacterial vaginosis is a vaginal infection and is most likely to affect women between the ages of 15 and 44 years."
The current Bacterial Vaginosis treatment market is dominated by Antibiotics (metronidazole), as these are the mainstay of Bacterial Vaginosis therapy. Medications include metronidazole, clindamycin oral or vaginal suppositories, and metronidazole vaginal gel. Metronidazole and clindamycin are the preferred medications used to treat Gardnerella infections. Metronidazole is the most common antibiotic for Bacterial Vaginosis. Clindamycin is an alternative antibiotic. It may be used if metronidazole is not effective, or if the infection recurs. Tinidazole is another antibiotic that is sometimes used Bacterial Vaginosis for treatment if metronidazole does not work. It's common for the disease to recur within three to 12 months, despite Bacterial Vaginosis treatment. This may be treated with a 7-day course of oral or vaginal metronidazole or clindamycin. If the previous treatment was by mouth, vaginal treatment might work better the second time, and if the first treatment was vaginal, the follow-up treatment should be by mouth.
The oral metronidazole can cause some minor but unpleasant side effects and recurrence of the disease is possible even after successful Bacterial Vaginosis treatment. More than half of those treated experience recurrent symptoms within 12 months. It is unclear why so many recurrent infections develop. Bacterial Vaginosis therapeutic options remain extremely limited, new drugs have not been forthcoming and are not likely to be available in the near future. Probiotics, although attractive as supplementary agents, have not consistently been shown to be advantageous. On the other hand, increasing recognition of the potential role of pathogen-rich biofilm in facilitating disease persistence, together with the future introduction of effective antibiofilm agents, results in hope for improved therapeutic success in the future. Ultimately optimization of future Bacterial Vaginosis treatment strategies may require combination approaches, such as antibiotics given along with biofilm-disrupting agents. Finally, several studies have evaluated the clinical and microbiological efficacy of probiotics to treat and to prevent Bacterial Vaginosis recurrence. Despite the need for more clinical studies, probiotics should be considered as part of the approach to disease prevention, and as an adjunct to antimicrobial treatment.
The launch of the emerging therapies is expected to significantly impact Bacterial Vaginosis treatment scenario in the upcoming years:-
Drugs covered
1. LACTIN-V
And many others
The key players in Bacterial Vaginosis market are:
1. Osel
And many others
Table of contents
1. Report Introduction
2. Bacterial Vaginosis Market Overview at a Glance
3. Bacterial Vaginosis Disease Background and Overview
4. Bacterial Vaginosis Epidemiology and Patient Population
5. Bacterial Vaginosis Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.United Kingdom
5.3. Japan
6. Bacterial Vaginosis Treatment & Medical Practices
7. Bacterial Vaginosis Marketed Products
7.1. Secnidazole: Symbiomix Therapeutics
7.2. VivaGel: Starpharma Holdings Limited
7.3. Lyophilized Lactobacillus crispatus IP174178: IPRAD pharma
8. Bacterial Vaginosis Key Emerging Therapies
8.1. LACTIN-V: Osel
9. Bacterial Vaginosis Market Size
10. Bacterial Vaginosis Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Market Drivers
12. Market Barriers
13. Appendix
14. Bacterial Vaginosis Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight